MLTX vs ROL · $1.41B cap vs P/E 41, rev $1.99B
MoonLake Immunotherapeutics (MLTX) versus Rollins Inc (ROL) — a side-by-side from cached financials, not a winner call.
MoonLake Immunotherapeutics (MLTX) is a biotechnology company listed on US.
Rollins Inc (ROL) is a personal services company listed on NYSE.
MLTX does not have a complete income-statement cache yet.
Latest reported ROL revenue for 2026-06-30 was $1.99B. Net income was $251.7M. ROL currently screens at market cap $21.73B and trailing P/E 41.4.
MLTX currently screens at market cap $1.41B. ROL currently screens at market cap $21.73B and trailing P/E 41.4.
Not investment advice. Open the MLTX and ROL stock pages for the full models.
Not investment advice.